A Case of Daratumumab-Induced Significant Decrease in Donor-Specific HLA Antibodies and Remission Induction Before Haploidentical Stem Cell Transplantation in a Refractory B-ALL Patient
Objective: To explore the method of eliminating donor-specific anti-HLA antibodies (DSA) in haploidentical stem cell transplantation (haplo-SCT). Methods: We present a refractory B-cell acute lymphoblastic leukemia (ALL) patient who had strongly positive DSA, but had no human leukocyte antigen–match...
Main Authors: | Xin Li, Haibo Zhu, Tao Sui, Xingli Zhao, Qi Deng |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2022-10-01
|
Series: | Cell Transplantation |
Online Access: | https://doi.org/10.1177/09636897221132502 |
Similar Items
-
PTCY-Based Haploidentical Donor Transplantation versus HLA-Matched Related and Unrelated Donor Transplantations in Patients with Refractory or Relapsed Lymphoma—A Matched-Pair Analysis
by: Sarah Haebe, et al.
Published: (2023-10-01) -
Daratumumab for donor-specific anti-HLA antibody desensitization in a case of HLA-mismatched allogeneic stem cell transplantation
by: Uroosa Ibrahim, et al.
Published: (2023-10-01) -
Effects of anti-HLA donor-specific antibodies and desensitization on engraftment of haploidentical hematopoietic stem cell transplantation
by: MA Yao, et al.
Published: (2024-02-01) -
Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
by: Kristine A. Frerichs, et al.
Published: (2021-05-01) -
Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of the EBMT
by: Mohamed A. Kharfan-Dabaja, et al.
Published: (2023-07-01)